2. Search Result
Search Result
Results for "

carboxypeptidase-b

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

4

Peptides

1

Natural
Products

5

Recombinant Proteins

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2746
    Carboxypeptidase B, Porcine pancreas

    EC 3.4.2.2

    		 Endogenous Metabolite Metabolic Disease
    Carboxypeptidase B, Porcine pancreas (EC 3.4.2.2) is a peptide exonuclease that can specifically degrade peptide chains. Carboxypeptidase B is progressively degraded from the C-terminal to release free amino acids. Carboxypeptidase B hydrolyzes only peptide bonds with basic amino acids (such as arginine and lysine) as C-terminal residues .
    Carboxypeptidase B, Porcine pancreas
  • HY-114118S1
    Semaglutide-d8 tetraTFA

    		Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8 tetraTFA
  • HY-114118S
    Semaglutide-d8

    		Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8
  • HY-E70201
    Carboxypeptidase B (MS grade)

    EC 3.4.2.2 (MS grade)

    		 Endogenous Metabolite Others
    Carboxypeptidase B (MS grade) is a peptide exonuclease that can specifically degrade peptide chains. Carboxypeptidase B (MS grade) is progressively degraded from the C-terminal to release free amino acids. Carboxypeptidase B (MS grade) hydrolyzes only peptide bonds with basic amino acids (such as arginine and lysine) as C-terminal residues .
    Carboxypeptidase B (MS grade)
  • HY-P4522
    Bz-Ala-Arg

    		Biochemical Assay Reagents Others
    Bz-Ala-Arg is a dipeptide. Bz-Ala-Arg is also a substrate of human pancreatic carboxypeptidase B and plasma carboxypeptidase N .
    Bz-Ala-Arg
  • HY-P4522A
    Bz-Ala-Arg TFA

    		Biochemical Assay Reagents Others
    Bz-Ala-Arg TFA is a dipeptide. Bz-Ala-Arg TFA is also a substrate of human pancreatic carboxypeptidase B and plasma carboxypeptidase N .
    Bz-Ala-Arg TFA
  • HY-122369
    Histargin

    		Carboxypeptidase Metabolic Disease
    Histargin is a selective carboxypeptidase B inhibitor with an IC50 of 17 μg/mL and a Ki of 30 μM. Histargin exerts competitive inhibition with substrate, with inhibitory activity abolished by metal cations. Histargin shows no significant inhibitory activity against carboxypeptidase A, aminopeptidase A, or aminopeptidase B .
    Histargin
  • HY-P2746A
    Carboxypeptidase-B rat

    		Carboxypeptidase Others
    Carboxypeptidase-B rat (EC 3.4.17.2) catalyzes the hydrolysis of the basic amino acids, lysine, arginine, and ornithine from the C-terminal position of polypeptides. Carboxypeptidase-B rat (EC 3.4.17.2) may be used for sequence analysis by successive cleavage of C-terminal basic amino acids.
    Carboxypeptidase-B rat
  • HY-129748
    SQ-24798

    		Carboxylesterase (CES) Others
    SQ-24,798 is a compound that inhibits carboxypeptidase B with high affinity and specificity. Its inhibitory effect may be achieved through the binding of the sulfhydryl group to the zinc ion of the enzyme and specific side chains.
    SQ-24798
  • HY-176313S
    Carboxypeptidase B2, Arg-13C6,15N4, Lys-13C6,15N2

    		Isotope-Labeled Compounds Cardiovascular Disease
    Carboxypeptidase B2, Arg- 13C6, 15N4, Lys- 13C6, 15N2 is the 13C-labeled and 15N-labeled Carboxypeptidase B2.
    Carboxypeptidase B2, Arg-13C6,15N4, Lys-13C6,15N2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: